• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a combination preparation for improving the egg cell quality and egg maturity comprising at least the active ingredients C vitamins, E vitamins, B1 vitamins, B2 vitamins, B5 vitamins, B6 vitamins, B9 vitamins, B12 vitamins, D vitamins and at least one ubiquinone-10 component containing B7 vitamins.
    公开号:AT510810A1
    申请号:T1312/2011
    申请日:2011-09-13
    公开日:2012-06-15
    发明作者:Birgit Dr Wogatzky；Johannes Dr Wogatzky
    申请人:Gonadosan Gmbh；
    IPC主号:
    专利说明:

    The invention relates to a combination preparation for improving egg cell quality comprising at least the active ingredients C vitamins, E vitamins, B1 vitamins, B2 vitamins, B5 vitamins, B6 vitamins, B9 vitamins, B12 vitamins, D vitamins, at least a Ubiquinone 10 component and B7 vitamins.
    More and more couples make the path to the desired child difficult. In industrialized countries such as Germany and the USA, one in ten couples is unintentionally childless and the trend is rising. Limited fertility can have many causes. The increasing age of couples wishing to have children may play a role as well as environmental pollution, reduced sperm quality, impaired ova, unhealthy lifestyles and others. So-called "lifestyle factors" are also a decisive factor. One of the prerequisites for fertility in men and women is adequate supply of the body with certain micronutrients, energy substrates and vitamins. A sufficient supply of vitamins and certain nutrients is increasingly difficult in our time. With increased stress in everyday life with stress, low food quality and unhealthy diet, the human organism is often inadequately supplied. As a result, the body is under constant load and this is especially true where the cells are most sensitive - in the egg and sperm cells. The male sperm become sluggish, oocytes "miss" their ovulation and thus fertility can suffer from malnutrition. It has already been proven in several studies, how much the right nutrition contributes to the fulfillment of the desire to have children. While the woman is already born with the egg cells, the sperm are imitated in the man for a lifetime. Therefore, it is important for the woman to prepare her body for pregnancy. There are a variety of combination preparations. They contain a combination of micronutrients necessary for the healthy development of oocytes.
    For example, US 2007/0104801 A1 discloses an agent for maintaining and increasing female fertility which, in addition to glucosamine sulfate, also contains selenium, folic acid, vitamin B6, vitamin B12, iron, zinc, magnesium, green tea, chaste tree and hyaluronic acid. US Pat. No. 6,569,857 B1 also discloses a dietary supplement for increasing the conception probability and for supporting a normal development of an embryo, whereby besides the vitamins E, C, B1, B2, B3, B6, B9, B12, also β-carotene, iron, copper , Zinc, calcium, magnesium, linolenic acid and DHA can be included.
    AU 2008/100822 A4 describes in a first embodiment a dietary supplement for women to facilitate the conception comprising vitamins B1, B2, B3, B5, B6, C, D, E, B9, iron, iodine, selenium, manganese, magnesium copper and Zinc, essential fatty acids and coenzyme Q10. Optionally, vitamin B12 may be included. It is further stated that, because of the hydrophilic and hydrophobic properties of the active ingredients, it is advantageous to combine only selected active ingredients in one formulation and to use a plurality of formulations, eg. As a tablet and a capsule. It is disclosed which active ingredients should be combined in one and the same formulation. In particular, the interaction of coenzyme Q10 with some vitamins and minerals is highlighted, which influence the shelf life of coenzyme Q10 and should therefore be contained in coenzyme Q10 in the other formulation. When biotin (vitamin B7) is used, it is preferably included in the first formulation containing vitamins and minerals.
    Women with specific illnesses who want to have children also have special needs. For example, women with autoimmune thyroiditis need treatment tailored to their condition. Chronic autoimmune thyroiditis is an autoimmune thyroid disease. In this case, the immune system forms so-called autoantibodies, which N2011 / 19300 -3 "*" * φ Φ · φΦ · Φ φφφφ
    Thyroid cells can attack and destroy. Two classic forms are most frequently observed. On the one hand the so-called Hashimoto's thyroiditis and on the other the Basedow's thyroiditis. The distinction of these two thyroid disorders can be very difficult in a particular case and there are even some overlapping forms.
    It is estimated that every sixth woman is predisposed to autoimmune thyroiditis and up to ten percent of them actually develop autoantibodies. The causes and triggers of autoimmune thyroiditis are still largely unclear. An association with genetic factors, diabetes, changes in sex hormones during pregnancy or menopause, smoking and radiation is discussed.
    The complaints are varied and vary individually. For women who want to have children, however, the main focus is on cycle disorders and unwanted childlessness. The risk of a miscarriage is also significantly increased.
    Before and during pregnancy, both healthy women and women with specific illnesses will benefit from a sufficient and appropriate level of essential nutrients and vitamins for the health of the growing baby. However, in some cases, excessive vitamin use may even be detrimental to egg quality.
    It is therefore an object of the present invention to provide a combination preparation which improves oocyte quality, increases fertility and reduces the risk of miscarriage.
    The object of the invention is in each case independent by a combination preparation for improving the egg cell quality and egg maturity comprising at least the active ingredients C vitamins (ascorbic acid), E vitamins (tocopherol), B1 vitamins (thiamine), B2 vitamins (riboflavin), B5- Vitamins (pantothenic acid), B6 vitamins (pyridoxine), B9 vitamins (folic acid), B12 vitamins (cobalamin), D vitamins (cal-ciferol, especially cholecaiciferol) and at least one ubiquinone-10-N2011 / 19300 -4- -4- • · • ♦ · · · · · · · · · · · · · · · · · · · · ·
    Component, wherein B7 vitamins (biotin) are included, and its use is solved. The advantage here is that the combination of the above-mentioned active ingredients in a preparation, the synergistic effect comes to advantage. Through the combination of active ingredients, simultaneous release and thus bioavailability provide the female organism with an optimum of active ingredients to improve egg quality, increase fertility and reduce the risk of miscarriage. The therapeutic effects are described below: It is advantageous that the supplementation of a ubiquinone-10 component benefits the female ovaries and thus improves both egg cell quality and egg cell maturity. The Ubiquinone-10 component is an important micronutrient for the mitochondria. The female germ cells have most of the body cells with the most mitochondria. Damage to the mitochondria leads on the one hand to lower energy supply and on the other hand to increase oxidative stress and thus to the formation of oxygen radicals in the oocytes. The additional intake of a ubiquinone-10 component has been shown to benefit the ovaries. Oxygen radicals, which, as already mentioned, are formed, attack the egg cell membrane. Furthermore, they impede mitochondrial function and adversely affect the integrity of DNA and RNA as well as the formation and function of cellular proteins. Many vitamins, especially vitamins C and E have been shown to have high antioxidant potential. Oxidative stress intensifies the autoimmune process, while antioxidants have a favorable effect on the course of the disease. Among other things, vitamins B6, B12 and folic acid of the B complex have a regulating effect on homocysteine metabolism. This has a positive effect on the vascular function and thus supports a sufficient circulation of the ovaries. Also, the implantation of the embryo in early pregnancy is positively influenced by a balanced homocysteine metabolism. In particular, in patients with a folate metabolic disorder (MTHFR gene mutation), the formation of microthrombi can be reduced during implantation and thus the early laboratory rate can be reduced by the vitamin B series. Vitamin B6 deficiency may increase homocysteine levels
    This may contribute to infertility, increased abortion, and disruption of placental function. Folic acid deficiency can lead to neurological malformations {u.a. Spina bifida) and other disorders in the newborn. Vitamins of the D complex show beneficial effects on the hormonal system and on the phosphate balance and calcium metabolism, which plays an important role in pregnancy (e.g., for building the skeletal system). Furthermore, the vitamin D system is important for the development and function of the nervous and muscular systems. B7 vitamins play an important role in the metabolism as a prosthetic group of enzymes, but are also important in the nucleus for the epigenetic regulation of gene function. Biotin deficiency impairs fertility and leads to an increased malformation rate. Patients with active autoimmune thyroiditis are more likely to have vitamin B12 deficiency than healthy individuals. Thiamine or vitamin B1 is a water-soluble vitamin and is indispensable especially for the function of the nervous system. Vitamin B2 or riboflavin serves as a precursor for important coenzymes. As a result, it plays a central role in metabolism. Vitamin B5 or pantothenic acid consists of the two components pantoic acid and β-alanine. Pantothenic acid is necessary for the development of coenzyme A, which plays an important role in the metabolism. It is involved in the assembly and disassembly of carbohydrates, fats, amino acids and the synthesis of cholesterol, which is needed for the formation of steroid hormones. In addition, it is advantageous for the combination preparation that the specific combination of the selected active ingredients shows better results than in comparison to the individual substances. Thus, a phase-appropriate care of the woman with vitamins, especially before, but also during pregnancy, available.
    The combination preparation is preferably used for the treatment of female infertility, especially for women over 35 years, whereby a later desire for children can be supported. Ubiquinone-10 components are needed by the body for, among other things, the generation of energy in the mitochondria. In particular, women of advanced childbearing age have increased mitochondrial damage (Seifer et al., 2002), which on the one hand leads to reduced energy supply and, on the other hand, to increased oxidative toxicity Lead to stress in the oocytes. This manifests itself in a reduced egg cell quality and impaired early embryonic development. Studies have shown that this is one of the main reasons for the age-related decline in female fertility (Bentov et al, 2010). To promote mitochondrial function, a ubiquinone component is used in the combination preparation. Ubiquinone 10 components are very good antioxidants, but are also needed by the body for energy in the mitochondria. Pignatti et al showed in 1980 that the tissue concentration of ubiquinone decreases with age. Santos-Ocana confirmed earlier observations in 2002 that make it clear that Ubiquinone is very important for mitochondrial energy delivery. The ubiquinone-10 component may consist of ubiquinone-10 or ubiquinol or a mixture of these compounds, whereby ubiquinol can be absorbed more rapidly and is thus immediately available.
    Advantageously, the ubiquinone-10 component proves to be administered in daily doses of 20 mg to 100 mg, in particular 30 mg to 50 mg, preferably 35 mg to 40 mg, which ensures that an appropriate level of the ubiquinone 10 component in the Organism is present and thus support for mitochondrial function, especially in the ovaries, can be done. This promotes good egg quality.
    The Ubiquinone 10 component is contained in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt .-%, preferably 8 to 12 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, on the one hand a sufficient effect of the Ubiquinon 10 component is given, but on the other hand, there is no risk of overdose. Due to the selected proportion by weight, there is also good processability in the preparation of the combination preparation.
    By the inventive selection of the amounts of the active ingredients, such as C-vitamins in amounts of 4 to 60 wt .-%, in particular 10 to 45 wt .-%, preferably 19 to 31 wt .-%, E-vitamins in amounts of 1 to 15% by weight, in particular 2N2011 / 19300
    Up to 10 wt .-%, preferably 3 to 6 wt .-%, B1 vitamins in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9 wt .-%, B2 vitamins in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9 wt .-%, B5 vitamins in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 2 to 3 wt .-%, Ββ-vitamins in amounts of 0 , 1 to 5 wt .-%, in particular 0.5 to 3 wt -%, preferably 0.8 to 1.3 wt .-%, B9 vitamins in amounts of 0.01 to 1 wt .-%, in particular 0.05 to 0.5 wt .-%, preferably 0.1 to 0.3 wt .-%, B12 vitamins in amounts of 0.0003 to 0.01 wt .-%, in particular 0.0009 to 0.005 wt .-%, preferably 0.001 to 0.008 wt .-%, B7 vitamins (biotin) in amounts of 0.001 to 0.5 wt .-%, in particular 0.007 to 0.1 wt .-%, preferably 0.01 to 0, 08, D vitamins in amounts of 0.0002 to 0.01 wt .-%, in particular 0.0008 to 0.008 wt .-%, preferably 0.001 to 0.005 wt .-%, and a Ubiquinone 10 component in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt .-%, preferably 8 to 12 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, show advantageous effects on egg maturity , Egg cell quality, fertility, and support of early embryonic development. The effectiveness of the combination preparation is based not only on the antioxidant activity of selected individual substances, but also on numerous other factors, such as. the correct delivery, in particular the delayed release of C-vitamins. The development and maturation of the egg is dependent on the presence of a certain amount of oxygen radicals, which is why a relatively small amount of the antioxidant vitamin C is included. Nevertheless, good protection against oxidative stress is given by a delayed release which does not start completely immediately after taking the combination preparation. Due to the balance and the selected composition, the desired effect can be achieved.
    Also advantageous is the addition of niacin in amounts of 1 to 20 wt .-%, in particular 3 to 15 wt .-%, preferably 5 to 11 wt .-%, zinc and / or a zinc compound in amounts of from 0.2 to 5 wt .-%, in particular 1 to 4.5 wt .-%, preferably 1.5 to 3.5 wt .-%, magnesium and / or a Magnesi- N2011 / 19300 -8 -. ·· ···· ···* -8th - . ····································· compound in amounts of from 10 to 50% by weight, in particular from 15 to 40% by weight, preferably from 25 to 35% by weight, of calcium and or a calcium compound, in amounts of 5 to 50 wt .-%, in particular 15 to 40 wt .-%, preferably 20 to 33 wt .-%, and / or nicotinic acid in amounts of 1 to 15 wt .-%, in particular From 2 to 10% by weight, preferably from 3 to 6% by weight, iodine and / or an iodine compound in amounts of from 0.001 to 0.1% by weight, in particular from 0.007 to 0.08% by weight, preferably 0, 01 to 0.05 wt .-%, iron and / or an iron compound in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 1.5 to 3 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, because thereby the previously described beneficial effects are expressed cumulatively on the development of the egg. The described composition of the combination preparation optimizes the interaction of the individual substances with one another and additionally reinforces the synergy effects. In addition, a balanced interaction with the other substances can be achieved. Niacin (vitamin B3) and nicotinamide, for example, enhance the antioxidant effect and support the regeneration of the DNA. For other substances, which are increasingly needed during pregnancy, such as magnesium, is given before the onset of adequate care.
    In pregnancy, there is often a shortage of this mineral. Many pregnant women do not take the recommended daily dose. Added to this are the increased magnesium requirement of the child and the increased magnesium excretion (by up to 25%) of the mother during pregnancy. In magnesium deficiency, one can often observe "muscular over-excitability". The first signs are, for example, calf cramps. These muscular disorders can also affect the uterine muscles. Premature labor and thus the risk of miscarriage and premature birth can be the result. Iron improves women's fertility. The need for iron doubles during pregnancy. Insufficient supply of this mineral leads to the so-called pregnancy anemia. Women with iron deficiency also have reduced fertility. Iodine influences the hormone balance. N2011 / 19300 4 · -9- 9 99 • · · · * * ♦ ·· * · · · · · · · Λ I ♦ · * · ···· ·· «·
    The addition of further trace elements selected from a group comprising selenium and / or a selenium compound in amounts of 0.001 to 0.05 wt .-%, in particular 0.002 to 0.01 wt .-%, preferably 0.003 to 0.005 wt .-%, Copper and / or a copper compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, molybdenum and / or a molybdenum compound in Amounts from 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, chromium and / or a chromium compound in amounts of 0.0001 to 0 , 5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, phosphorus and / or a phosphorus compound in amounts of 0.1 to 30 wt .-%, in particular 1 to 20 wt .-%, preferably 10 to 15 wt .-%, manganese and / or a manganese compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight of the therapeutically active agent Fe of the combination preparation can further improve the beneficial effects on the egg, in particular the egg cell quality. Trace elements are essential nutrients for humans, the absence of which can cause severe deficiency symptoms. Daily high-dose selenium intake may improve symptoms of Hashimoto's thyroiditis (Gärtner et al., 2002, Duntas et al., 2003). For this positive effect, two properties of selenium seem to be responsible. Firstly, it is needed by the selenium-dependent enzyme iodothyronine deiodase for the conversion of the thyroid hormone T4 (storage form) into the active-exchange active form T3. If the selenium level is too low, sufficient T3 can not be produced from the existing T4. In addition, selenium, as part of the enzyme glutathione peroxidase, can lower the specific antibodies responsible for autoimmune thyroiditis. It acts as an antioxidant and captures harmful radicals that are produced in the thyroid gland as a by-product of the formation of thyroid hormones. This improves the functioning of the immune system (Gärtner et al., 2002, Turker et al., 2006). The soils in Europe are very low in selenium, so that in plants that grow on these soils, and thus in the diet, little selenium is present. In inflammatory conditions, N2011 / 19300
    In addition, there is an increased need for diseases such as Hashimoto's thyroiditis, which certainly can not be met by the normal diet.
    The addition of precursors of A vitamins, in particular α- and β-carotene, α- and β-cryptoxanthin and lycopene, in amounts of 0.0001 to 0.05 wt .-%, in particular 0.0002 bis proves to be advantageous 0.001 wt .-%, preferably 0.0003 to 0.0006 wt .-%, and / or K vitamins, in particular K1, K2, K3 in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation, because the use of estrogen, the utilization of A vitamins may be disturbed and by admixing A vitamins to Combination preparation is nevertheless provided for an adequate supply of A vitamins and thus can exert their positive effects on growth.
    Omega-3 fatty acids, in particular DHA and / or EPA, in amounts of 2 to 70 wt .-%, in particular 10 to 50 wt .-%, preferably 20 to 40 wt .-%, based on the total weight of the therapeutically effective Active ingredients of the combination preparation, it is ensured even before the onset of pregnancy that adequate care is given and thus the increased need during pregnancy is already covered at the beginning. However, administration of omega-3 fatty acids is not recommended until the third month of pregnancy and can then also promote the neurological development of the fetus.
    By adding probiotics in amounts of 0.1 to 10 wt .-%, in particular 0.5 to 5 wt .-%, preferably 1 to 3 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation is achieved in that the mucosal immune system is stimulated or modulated. Even vaginal infections can be positively influenced by probiotics and thus create a more favorable environment for pregnancy.
    For the purposes of the invention, all representatives known to these vitamins are understood as pre-A, B, C, D and E vitamins. For example, N2011 / 19300 • · -11 ··· * * + + E vitamins are said to comprise tocopherols, tocotrienols and tocomonoenols.
    By the term D-vitamins in particular vitamin D3, 25 (OH) vitamin D3 and calcitriol are included. This is mentioned only as an example and also applies to the other vitamins mentioned in the invention.
    The same as described above also applies to the other active substances mentioned in the invention, where their derivatives or salts should also be included, which are bioavailable to the body for disposition.
    Among other things, the present invention describes the positive effect of ubiquinone-10 components on the oocyte, in particular the maturation of the oocyte and the early embryonic development and implantation. A Ubiquinone-10 component is required by the body for, among other things, energy production in the mitochondria. It is an important micronutrient for the support of mitochondrial health. Of all body cells, the female ova have the most mitochondria. However, women of advanced childbearing age, in particular, show increased mitochondrial damage leading, on the one hand, to reduced energy supply and, on the other hand, to increased oxidative stress in the oocytes. This manifests itself in a reduced egg cell quality. This is a major cause of the age-related decline in female fertility. The ubiquinone-10 components decrease with age and this explains the beneficial effect of ubiquinone supplementation in women over 35 with desire to have children. Ubiquinone 10 components are also an important antioxidant.
    Various processes such as environmental pollution, malnutrition, radiation and other stresses lead to oxidative stress in the body. This refers to damage to cells by oxygen radicals and other reactive oxygen species. In particular, the germ cells, sperm and egg cells, are particularly vulnerable here. Like male fertility, female fertility is also adversely affected by oxidative stress. The normal age-related decline in women's fertility is related, inter alia, to oxidative damage. This could be proved by scientific research. * * * * »« * * * * * * * * * * * * * * * * * * I I I I I I I I I I I I I I I I I I · Φ φ Φ * * ·
    Studies are proven beyond doubt. Usually, the body has a number of its own defense mechanisms, including the body's own antioxidants - but these are, especially in advanced age, not always sufficiently available.
    The combination preparation according to the invention is specially developed for the needs of the female body in the case of the desire to have children and pregnancy. It can be either a dietary supplement, a dietary supplement for special medical purposes (complementary balanced diet), or a medicinal product. This ensures for the user that the drug has undergone at least one clinical trial in the case of approval as a drug or balanced diet and that a simple and possibly discrete access to the drug is given when approved as a dietary supplement.
    Owing to the combination preparation according to the invention, oocytes are protected against harmful influences by oxidative stress and at the same time supplied with the nutrients and minerals necessary for the development in order to enable them to develop as best as possible.
    Furthermore, the combination preparation according to the invention shows a specially adapted mixture of antioxidants, partly in depot form, and other important nutrients and minerals for the reproductive cells. Thus, for example, vitamin C is added as a sustained-release form, whereby the body is time-delayed throughout the day distributed sufficient vitamin C available and not immediately after taking the combination preparation circulates the entire amount in the bloodstream. The prolonged release of vitamin C is particularly beneficial because an excess of antioxidants can also be harmful. Preparations for a sustained release of active ingredients are described in the prior art. For example, vitamin C may be coated with hydroxypropylmethylcellulose. Of course, other known from the prior art methods for the delayed release of vitamin C can be applied. For fertility-enhancing products, however, the use of the prior art vitamin C form of vitamin C has hitherto not been known.
    The mechanisms of action of the individual substances in the combination preparation according to the invention are complex. In addition to nutrient administration and enzyme induction, an essential mechanism of action is the targeted reduction of oxygen radicals.
    All individual substances in the combination preparation according to the invention have been shown in studies that an additional intake of the antioxidants in the combination preparation according to the invention leads to a significant improvement in their fertility in women.
    The mechanisms described above work preferably in combination of the active ingredients and by supporting several antioxidants. Other substances such as zinc, which is involved in almost all biochemical processes in the body and is a component of antioxidant enzymes, support the effect of the combination preparation according to the invention. Zinc can not be stored in the body, it must be regularly supplied from outside. Due to wrong eating habits zinc deficiency is not even in western countries. In the case of Hashimoto's thyroiditis, the timely supply of zinc makes sense, since this trace element plays a crucial role in the immune system and zinc also has a central importance for the metabolism of thyroid hormones. Several animal studies in rats have shown that hypothyroidism is associated with poorer zinc status compared to a balanced thyroid metabolism.
    Due to the synergistic effect of the individual active ingredients in the selected quantitative ranges, the effectiveness with respect to egg cell quality and egg maturity of the combination preparation according to the invention can be achieved.
    The combination preparation is preferably taken orally. The preparation can be used both as a human and veterinary product.
    The following table shows the quantitative ranges of the recommended daily dose of the individual active substances relevant for the invention. In any case, the combination preparation contains the active ingredients C vitamins, E vitamins, B1 vitamins, B2 vitamins, Βδ vitamins, N2011 / 19300 -14- # fr ·· w fr * «#« * B6 vitamins, B9 vitamins B12 vitamins, D vitamins, at least one Ubiquinone 10 component and B7 vitamins. The other listed active substances, which may optionally be included, include lower and upper limits. Preferably, the combination preparation according to the invention is taken as one capsule per day. However, drug levels can be chosen to require two capsules per day to achieve the recommended dosage.
    Active ingredient Recommended amount range in mg per day Vitamin C 80 -120 Vitamin E 10-30 Vitamin B1 1-3 Vitamin B2 1.5-3 Vitamin B5 6-18 Vitamin B6 3-5 Vitamin B12 0.005-0.008 Vitamin B9 0 CD 1 I 00 i Vitamin D 0.003 - 0.006 Vitamin B7 0.1-0.2 Ubiquinone-10 Component 30-50 Niacin 15-40 Zinc 5-20 N2011 / 19300 -15- -15- • »« • · · • I · • * * * * * * «* II * w 4 * * ·» «* · ·· ft ··» «···
    Magnesium 100-300 Iodine 0-0.15 Iron 5-15 Be 0.01-0.2 Calcium 100-400 Omega-3 fatty acids 200 - 500 Vitamin A 0.01-0.5 Nicotinic acid amide 15-36 Vitamin K 0.01-0.1 copper 0.5-3 molybdenum o 0 1 o -1. Chromium o 0 1 © ß-carotene 1-5 Probiotics 0.1-10 Phosphorus 50-150 Manganese 0.5-3
    In the following, exemplary embodiments of the composition of the therapeutically active substances of the combination preparation according to the invention are mentioned, which achieves the advantageous effects.
    They are also excipients, such as auxiliaries, fillers, carriers, binders, etc., which can be used for the industrial processability of the combination composition according to the invention. N2011 / 19300 *. * *. * *. * * * * * * * * · · · • 4 «44 • ft · * ····
    Preparation are required. However, these excipients have no therapeutic efficacy and no positive effects on the egg cell quality and are therefore not therapeutically active agents in the context of the invention.
    The following tables show 20 embodiments, indicating the absolute numbers of therapeutically active agents.
    Active ingredient 1 2 3 4 5 6 7 8 9 10 Vitamin C " 80 100 120 95 80 100 120 80 100 Vitamin E - 10 20 30 25 10 20 30 10 20 Vitamin B1 1 3 3 2.5 1 3 3 1 3 Vitamin B2 "1.5 3 3 2 1.5 3 3 1, 5 3 Vitamin B5 6 12 18 15 6 12 18 6 12 Vitamin B6 "3 4 5 3 3 4 5 3 4 Vitamin B12 - 0.005 0.007 0.008 0.006 0.005 0.007 0.008 0.005 0.007 Vitamin B9" 0.6 0.8 0.8 0 , 7 0.6 0.8 0.8 0.6 0.8 Vitamin D _ 0.003 0.005 0.006 0.004 0.003 0.005 0.006 0.003 0.005 Niacin " - * 15 35 40 15 35 Vitamin B7 "- 0.1 0.2 0.2 0.1 0.2 Zinc - - ~ 14 5 5 20 5 5 Magnesium -" " - 100 100 300 100 100 Iodine "" 0,05 0 0,15 0,15 0 0,15 N2011 / 19300 -17-
    »· · · ** · * * ♦ · · · * ψ * ··· ♦ · *«
    Iron - - - "5 7,5 15 5 7,5 Ubiquinone-10 Component 50 30 35 50 40 30 35 50 30 35 Selenium " "" - "" - "Calcium -" • "250" "100 125 Omega-3 fatty acids Vitamin A" "" "" "" Nicotinic acid amide 10 20 Vitamin K "" "" "" Copper - "" "" "" - "molybdenum -" "" 0.4 - "" "chrome -" "" " "" • ß-Carotene "" - "- - Probiotics -" "" 4 • "•" "Phosphorus" • * "" "Manganese - *" "*" "" &Quot; "Fillers and carriers ν '✓ ✓ ✓ ✓ ν' ✓ Ν2011 / 19300 - 18- • * ♦ · · · · · · · ·
    Active ingredient 11 12 13 14 15 16 17 18 19 20 Vitamin C 120 96 80 100 120 85 105 100 115 95 Vitamin E 30 23 10 20 30 11 30 20 21 15 Vitamin B1 3 2 1 3 3 1 3 2 2 1,5 Vitamin B2 3 2 1.5 3 3 1.8 2.9 1.7 2.4 2.9 Vitamin B5 18 10 6 12 18 15 10 6 9 18 Vitamin B6 5 5 3 4 5 5 3.5 3 4.4 4 Vitamin B12 0.008 0.008 0.005 0.007 0.008 0.007 0.008 0.006 0.005 0.005 Vitamin B9 0.8 0.6 0.6 0.8 0.8 0.7 0.8 0.7 0.6 0.6 Vitamin D 0.006 0.004 0.003 0.005 0.006 0.005 0.003 0.006 0.004 0.003 Niacin 40 "15 35 40 22 38 34 17 Vitamin B7 0.2 0.1 0.2 0.2 0.15 0.11 0.12 - Zinc 20 5 5 20" - * Magnesium 300 "100 100 300 100 120 150 230" Iodine 0.15 • 0 0.15 0.15 " - "Iron 15 5 7.5 15 -" "" Ubiquinone-10 Component 50 42 30 35 50 50 40 32 46 Selenium 0.01 0.03 0.1 0.08 "N2Ö11 / 19300
    Calcium 500 120 100 120 500 - - - - - Omega-3 fatty acids 20 400 1000 300 Vitamin A · »0,001 0,001 0,001 0,01 - -" "Nicotinic acid amide 50 30 10 20 50 Vitamin K • 0,5 1 10 "4 - copper" 0.5 1 10 "0.5 ~ molybdenum - 0.01 0.08 0.5" "0.1 chromium" 0.1 0.01 0.06 0.5 0.09 " &Quot; &Quot; ß-carotene "0,5 2 10" 5 * "Probiotics -" 0 1 5 "-" - Phosphor "1 125 200 12 Manganese" "0,1 1 10" 0,9 "Fillers and carriers ✓ ν 'ν ✓ ✓ ✓ ✓
    In experiments could be demonstrated that the embodiments 7 and 10 show particularly good effectiveness. Thus, for example, with the composition according to Example 7, a 10% higher number of positive pregnancy tests after reproductive medical treatment could be achieved compared to a pure folic acid preparation or a simple multivitamin preparation. This result is confirmed by repetition as N2011 / 19300 «· -20-
    probably with women under 35 years as well as women over 35 years. In women over the age of 35 years, both the number of oocytes harvested after one stimulation cycle and the number of oocytes for metaphase II and the number of successfully fertilized oocytes can be increased by approximately 10%. Even with a composition according to embodiment 10 can be demonstrated that it comes by promoting the egg maturation to an increased by about 10% egg amount after stimulation in the context of a reproductive medical treatment and to about 10% increased fertilization rate. In general, it has been demonstrated that with the preparation according to the invention the egg cell quality is significantly improved in over 90% of women, in particular of over 35 years old.
    In the table below, the composition of the active compounds in absolute and relative numbers of a combination preparation according to the invention (exemplary embodiments 10 and 7) which exhibits the advantageous effects is described by way of example.
    Active ingredient Amount in mg% by weight Amount in mg% by weight Vitamin C 100 21.24666958 100 30.70668362 Vitamin E 20 4.249333917 20 6.141336723 Vitamin B1 (thiamine) 3 0.637400088 3 0.921200509 Vitamin B2 (Riboflavin) 3 0,637400088 3 0,921200509 Pantothenic acid B5 12 2,549,60035 12 3,684802034 Vitamin B6 (pyridoxine) 4 0,849,867,883 4 1,228267345 Vitamin B12 (cobalamin) 0,007 0,001487267 0,007 0,002149468 N2011 / 19300 • · -21 -
    Folic acid 0.8 0.169973357 0.8 0.245653469 Vitamin D 0.005 0.001062333 0.005 0.001535334 Niacin (nicotinic acid) 35 7.436334355 35 10.74733927 Biotin 0.2 0.042493339 0.2 0.061413367 Zinc 5 1.062333479 5 1.535334181 Magnesium 100 21.24666958 100 30.70668362 Iodine 0.15 0.031870004 0.15 0.046060025 Iron. 7.5 1.593500219 7.5 2.303001271 Ubiquinone 10 component (coenzyme Q10) 35 7.436334355 35 10.74733927 Calcium 125 26.55833698 " Nicotinamide 20 4,249,333,317 "
    In a preferred embodiment, the combination preparation according to the invention comprises magnesium oxide, L-ascorbic acid, coenzyme Q10 (7.5%), silica gel, iron citrate (5.2%), D-alpha-tocopheryl acetate, nicotinamide, calcium-D. pantothenate, nicotinic acid, zinc oxide, pyridoxine-HCf, thiamine-HCl, malto-dextrin, riboflavin, thickener gum arabic, sodium citrate, sucrose, corn starch, citric acid, pteroyl monoglutamic acid (0.17%), potassium iodide (0.05%), biotin , Antioxidant alpha-tocopherol, stabilizer tricalcium phosphate, dye titanium dioxide, dye sunset yellow S, cholecal-ciferol, cyanocobalamin. The capsule shell is preferably formed or coated from cellulose. N2Ö11 / 19300 • · • 9 -22- • · 9 9 9 »··· ♦ 9999
    The positive effect of the combination preparation according to the invention can be used both in preparation for a natural pregnancy and in preparation for insemination, in vitro fertilization and intracytoplasmic sperm injection.
    In one alternative, a combination preparation may be prepared which does not contain a ubiquinone-10 component. In any case, this combination preparation comprises C vitamins, E vitamins, B1 vitamins, B2 vitamins, B5 vitamins, B6 vitamins, B12 vitamins, B9 vitamins, D vitamins and niacin and possibly B7 vitamins, zinc, magnesium , Iodine, iron and / or calcium. The quantitative ranges of the active ingredients are the same as described above.
    Below are embodiments of this ubiquinone-10 component-free alternative, wherein the amounts are in mg / capsule.
    Active ingredient 21 22 23 Vitamin C 100 100 100 Vitamin E 20 20 20 Vitamin B1 3 3 3 Vitamin B2 3 3 3 Vitamin B5 12 12 12 Vitamin B6 4 4 4 Vitamin B12 0.007 0.007 0.007 Vitamin B9 0.8 0.8 0.8 Vitamin D3 0.005 0.005 0.005 Niacin 15 • 15 Ν2011Π9300 -23-
    Vitamin B7 0.2 - 0.2 Zinc 5 ~ 5 Magnesium 100 - 100 Iodine 0.15 "0.15 Iron 7.5 - 15 Nicotinamide 20 " 20 calcium 125
    In a development of this alternative, it is also possible for the active ingredients such as selenium, omega-3 fatty acids, A vitamins, K vitamins, copper, molybdenum, chromium, b-carotene, phosphorus, manganese and / or probiotics to be present in the previously described quantitative ranges be.
    This alternative also has a good effect on egg cell quality and egg maturity, although the success using a ubiquinone Q10 component is greater, especially in women over 35 years old.
    In another alternative, the combination preparation contains active ingredients adapted to the specific needs of women with desire to have children and active autoimmune thyroiditis. This variant of the combination preparation prepares the body by its particular composition for an impending pregnancy and promotes fertility. Treatment with thyroid hormones can in many cases enable pregnancy. In addition to this, certain vitamins and nutrients can have a positive effect on the course of the disease. It is important in this context, however, that the supply of iodine in the case of active ignition should be avoided in any case, because it can lead to a significant deterioration of the situation. Therefore, women with autoimmune thyroiditis require special, N2011 / 19300 -24 iodine-free preparations. In addition, daily increased selenium intake improves the symptoms of Hashimoto's thyroiditis. Patients with autoimmune thyroiditis show elevated levels of oxidative stress and reduced antioxidant levels. An additional supply of the body with antioxidants is therefore necessary and affects the disease in its course positively. At the same time, oocytes are protected from the harmful effects of oxidative stress. Patients with autoimmune thyroiditis are increasingly suffering from vitamin B12 deficiency. This is particularly problematic in the case of a desire to have children, since vitamin B12, in addition to its importance for cell division together with other vitamins of the B group, in particular vitamin B6 and folic acid, is indispensable for the regulation of homocysteine metabolism.
    Below are embodiments of the embodiment of the combination preparation for subjects with autoimmune thyroiditis, wherein the amounts are given in mg / capsule (except column 3).
    Active ingredient 24 24 (in% by weight) 25 26 Vitamin C 100 32,99088792 100 120 Vitamin E 20 6,598177583 20 30 Vitamin B1 3 0,989726638 3 4 Vitamin B2 3 0,989726638 3 2 Vitamin B5 12 3,95890655 12 15 Vitamin B6 4 1.319635517 4 5 Vitamin B12 0.009 0.00296918 0.009 0.01 Vitamin B9 0.8 0.263927103 0.8 0.8 N2011 / 19300 -25- «· · · · · · * * · • «·» ··· ····
    Vitamin D3 0.005 0.001649544 0.005 0.01 Niacin 35 11.54681077 15 Vitamin B7 0.2 0.065981776 0.2 0.3 Zinc 5 1.649544396 • 6 Selenium 0.1 0.032990888 0.2 0.05 Magnesium 100 32,99088792 "200 Coenzyme Q10 20 6,598177583 0,1 0,05 Iron 7,5 2,474316594 14 Nicotinamide - 20 Calcium - - · " 125
    The above-mentioned embodiments show particularly good effects in women with autoimmune thyroiditis and having children, both in spontaneous conception and in the context of reproductive medicine treatment. The above embodiments 24 to 26 contain a combination of micronutrients, which supports the healthy development of oocytes and favors the course of the disease in autoimmune thyroiditis. With the combination preparation according to exemplary embodiment 24, better results than with a combination preparation according to Examples 25 and 26 are achieved. This vital substance complex promotes fertility and contributes to the healthy development of the baby in the first few weeks.
    Preferably, the embodiments of the combination preparation are free of gelatin and lactose. N2011 / 19300 -26- ** «# ·« · · ·········································································· »
    All variants of the combination preparation should be taken orally once a day in the form of a capsule. The recommended minimum income is 1 to 3 months. The preparation should then continue to be taken when pregnancy occurs at least until the 12th week of pregnancy. All statements on ranges of values in the description of the present invention should be understood to include any and all sub-ranges thereof, e.g. the indication 1 to 10 should be understood to include all sub-ranges, starting from the lower limit 1 and the upper limit 10, i. all subregions begin with a lower limit of 1 or greater and end at an upper limit of 10 or less, e.g. 1 to 1.7, or 3.2 to 8.1 or 5.5 to 10.
    The Ausführungsbeispiete show possible embodiments of the combination preparation, it being noted at this point that the invention is not limited to the specifically illustrated embodiments thereof, but also various combinations of the individual embodiments are mutually possible and this variation possibility due to the teaching of technical action by representational Invention in the skill of those skilled in this technical field. So are all possible design variants, which are possible by combinations of individual details of the embodiment described, includes the scope of protection.
    The problem underlying the independent inventive solutions can be taken from the description. N2011 / 19300
    权利要求:
    Claims (15)
    [1]
    1.- * * * Λ (new) claims 1. Combination preparation for improving the EizeHqualität and egg maturity comprising at least the active ingredients C-vitamin, E-vitamins, B1-vitamin, B2-Vltamin, 85-vitamin, B6-Vrtamme, Βθ- Vitamin, B12-Vrtamine, D-vitamins and at least one ubiquinone-10 component and B7-vitamin in the treatment of female infertility, as well as to improve egg-egg quality and egg-maturity.
    [2]
    2. Combination preparation according to claim 1, characterized in that C-vitamin in amounts of 4 to 00 wt .-%, in particular 10 to 45 wt .-%, preferably 19 to 33 wt .-%, E-vitamins in amounts of 1 to 15 wt .-%, in particular 2 to 10 wt .-%, preferably 3 to 6 wt .-%, B1 vitamin in amounts of 0.1 to
    [3]
    3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9 wt -, B2 vitamin in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9 wt .-%, B5 vitamin in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 1.2 to 4 wt .-%, B6 vitamins in amounts of 0.1 to 5 wt .-%, in particular 0.5 to 3 wt .-%, preferably 0.8 to 1.3 wt .-%, B9-VItamin in Amounts of from 0.01 to 1% by weight, in particular from 0.05 to 0.5% by weight, preferably from 0.1 to 0.3% by weight, of B12 vitamins in amounts of from 0.0003 to 0, 01 wt .-%, in particular 0.0009 to 0.008 wt .-%, preferably 0.001 to 0.01 wt .-%, D-vitamins in amounts of 0.0002 to 0.01 wt -%, in particular 0.0008 to 0.008 wt .-%, preferably 0.001 to 0.01 wt .-%, a Ubiquinon-10 component in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt .-%, preferably 6 to 12 wt. -%, and B7-vitamin in amounts of 0.001 to 0.5 wt .-%, in particular 0.007 to 0.1 wt .-%, preferably 0.01 to 0.08, based on the Total weight of the therapeutically active agents of the combination preparation are included. FOLLOW-UP [A2011AH31Z iQir Aionio 11 07 Nr · R7fi5 P.014 / 020 11:25:27 18-04-2012 14/19 t I -2- 3. Combination preparation according to claim 2 or 3, characterized in that niacin, zinc and / or a zinc compound, magnesium and / or a magnesium compound, calcium and / or a calcium compound, iodine and / or an iodine compound, iron and / or an iron compound and / or nicotinamide.
    [4]
    4. Combination preparation according to claim 3, characterized in that niacin in amounts of 1 to 20 wt .-%, in particular 3 to 15 wt .-%, preferably 5 to 11 wt .-%, zinc and / or a zinc compound in amounts of 0.2 to 5 wt .-%, in particular 1 to 4.5 wt .-%, preferably 1.5 to 3.5 wt .-%, magnesium and / or a magnesium compound in amounts of 10 to 50 wt .-% , in particular 15 to 40 wt .-%, preferably 25 to 35 wt .-%, calcium and / or a calcium compound in amounts of 5 to 50 wt .-%, in particular 15 to 40 wt .-%, preferably 20 to 33 wt % and / or nicotinamide in amounts of 1 to 15% by weight, in particular 2 Ms 10% by weight, preferably 3 to β% by weight, iodine and / or an iodine compound in amounts of 0.001 to 0, 1% by weight, in particular 0.007 to 0.06% by weight, preferably 0.01 Ms0.05% by weight, of iron and / or an iron compound in amounts of 0.5 to 10% by weight, in particular 1 to 5 Gew%, preferably 1.5 to 3 Gew. -%, related to the total weight of the therapeutically effective agents of the combination preparation are included.
    [5]
    5. Combination preparation according to one of claims 1 to 4, characterized in that further trace elements selected from a group comprising selenium and / or a selenium compound, copper and / or a copper compound, molybdenum and / or a molybdenum compound, chromium and / or a chromium compound, Phosphorus and / or a phosphorus compound, manganese and / or a manganese compound or a mixture of two or more of these compounds is READY A2011 / D1312 P.015 / 020 11:26:) 3 18-04-2012 15/19 ·· · · * ♦♦ · ψ • * ψ ·· ··· * • · * V ·· * ·· »·· • * * * ** f * · I * # | φ ΦΦΦ t * ··· · I · »· · · ·· ♦« · · φ -3-
    [6]
    6. Combination preparation according to claim 5, characterized in that trace elements selected from a group comprising selenium and / or a selenium compound in amounts of 0.001 to 0.09 wt .-%, in particular 0.002 to 0.05 wt .-%, preferably 0.003 to 0.03 wt .-%, copper and / or a copper compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt. %, Molybdenum and / or a molybdenum compound in amounts of 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, chromium and / or a Chromium compound in amounts of 0.0001 to 0.5 wt .-%, in particular 0.001 to 0.1 wt .-%, preferably 0.002 to 0.05 wt .-%, phosphorus and / or a phosphorus compound in amounts of 0.1 to 30 wt .-%, in particular 1 to 20 wt .-%, preferably 10 to 15 wt .-%, manganese and / or a manganese compound in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 Wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight Not the therapeutically active agents of the combination preparation are included.
    [7]
    7. Combination preparation according to one of claims 1 to Θ, characterized in that precursors of A vitamins, in particular, a- and ß-carotene, a- and ß-Cryptoxenthin and lycopene, and / or K-Vrtamine, in particular K1, K2 , K3 based on the total weight of the therapeutically active agents of the combination preparation are included.
    [8]
    8. Combination preparation according to claim 7, characterized in that precursors of A vitamins, in particular, α- and β-carotene, α- and β-cryptoxanthin and lycopene, in amounts of 0.0001 to 0.05 wt .-%, in particular 0.0002 to 0.001 wt .-%, preferably 0.0003 to 0.0006 wt .-%, and / or K-Vltamine, in particular K1, K2, K3 in amounts of 0.05 to 3 wt .-%, in particular 0.08 to 1 wt .-%, preferably 0.1 to 0.5 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. POSSIBLE Α2011ΛΠ312 ia / n, i / 9ni9 11 -98 No · R7fi5 P.016 / 020 11:26:59 18-04-2012 16/19 11:26:59 18-04-2012 16/19 * · ♦ · * · · · # · «··« · · V · «# · * f
    [9]
    9. Combination preparation according to one of claims 1 to 8, characterized in that omega-3 fatty acids, in particular DHA and / or EPA, are included.
    [10]
    10. Combination preparation according to claim 9, characterized in that omega-3 fatty acids, in particular DHA and / or EPA, in amounts of 2 to 70 wt .-%, in particular 10 to 50 wt .-%, preferably 20 to 40 wt. -%, based on the total weight of the therapeutically active agents of the combination preparations are included.
    [11]
    11. Combination preparation according to one of claims 1 to 10, characterized in that probiotics in amounts of 0.1 to 10 wt .-%, in particular 0.5 to 5 wt .-%, preferably 1 to 3 wt .-%, based on the total weight of the therapeutically active agents of the combination preparations are included.
    [12]
    12. Combination preparation according to one of claims 1 to 11, characterized in that C-vitamin, E vitamins, B1 vitamin, B2 vitamin, B5 vitamin, Ββ vitamins, B9 vitamin, B12 vitamins, D vitamins , at least one ubiquinone-10 component, B7-vitamin, niacin, zinc, magnesium, iodine and iron are included.
    [13]
    13. Combination preparation according to claim 12, characterized in that C-vitamin in amounts of 4 to 60 wt .-%, in particular 10 to 45 wt .-%, preferably 19 to 33 wt .-%, E-vitamins in amounts of 1 to 15 wt .-%, in particular 2 to 10 wt .-%, preferably 3 to 6 wt .-%, B1 vitamin in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt. %, preferably 0.3 to 0.9 wt .-%, B2 vitamin in amounts of 0.1 to 3 wt .-%, in particular 0.2 bte 2 wt .-%, preferably 0.3 to 0.9 Wt .-%, B5 vitamin in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 1.2 to 4 wt .-%, Ββ vitamins in amounts of 0.1 up to 5% by weight, in particular from 0.5 to 3% by weight, in front of the surface. READER A2011 / 01312 11 9Q No · R7R.R P.017 / 020 • 4 * · * ·· + * 11:27:42 18 -04-2012 17/19 * * * · · · ♦ · · · · · «* ········································································································ Preferably, 0.8 to 1.3% by weight of B9 vitamin in amounts of 0 (01 to 1% by weight, in particular 0.05 to 0) , 5 wt .-%, preferably 0.1 to 0.3 wt .-%, B12-Vttamine in amounts of 0.0003 to 0.01 wt .-%, in particular 0.0009 to 0.008 wt .-%, preferably 0.001 to 0.01% by weight, D vitamins in amounts of 0.0002 to 0.01% by weight, in particular 0.0006 to 0.008% by weight, preferably 0.001 to 0.01% by weight, a ubiquinone-10 component in amounts of from 2 to 25% by weight, in particular from 5 to 15% by weight, preferably from 6 to 12% by weight, and B7-vitamin in amounts of from 0.001 to 0.5% by weight. %, in particular 0.007 to 0.1 wt .-%, preferably 0.01 to 0.08, niacin in amounts of 1 to 20 wt .-%, in particular 3 to 15 wt .-%, preferably 5 to 11 parts by weight. %, Zinc and / or a zinc compound in amounts of 0.2 to 5 wt .-%, in particular 1 to 4.5 wt .-%, preferably 1.5 to 3.5 wt .-%, magnesium and / or a Magnesium compound in amounts of 10 to 50 wt .-%, in particular 15 to 40 wt .-%, preferably 25 to 35 wt .-%, iodine and / or an iodine compound in amounts of 0.001 to 0.1 wt .-%, in particular 0.007 to 0.08 wt .-%, vo Preferably 0.01 to 0.05 wt .-%, and iron and / or a Eisenverfoindung in quantities ναι 0.5 to 10 wt .-%, in particular 1 to 5 wt .-%, preferably 1.5 to 3 wt. -%, based on the total weight of the therapeutically active agents of Kbmbinationspräparats are included.
    [14]
    14. Combination preparation according to one of claims 1 to 11, characterized in that C-vitamins, E-vitamins, Bl-Vrtamine, B2-vitamins, Bo-vitamins, B6-Vftamjne (B9 vitamins, B12 vitamins, D vitamins , at least one ubiquinone-10 component, B7-vrtamine (niacin, zinc, magnesium, iron and iron are included.
    [15]
    15. Combination preparation according to claim 14, characterized in that vitamins in amounts of 4 to 60 wt .-%, in particular 10 to 45 wt .-%, preferably 19 to 33 wt .-%, E-Vrtamine in amounts of 1 to 15 wt .-%, in particular 2 to 10 wt .-%, preferably 3 to 6 wt .-%, B1 vitamins in amounts of 0.1 to 3 wt .-%, in particular 0.2 to 2 wt .-%, preferably 0.3 to 0.9% by weight, B2-trietamines in amounts of from 0.1 to 3% by weight, in particular from 0.2 to 2% by weight, of Na / Na / omo 11 -an No. R7fiR P.018 / 0-20 11:28:30 18-04-2012 18/19 • · * · 6 wt .-%, preferably 0.3 to 0.9 wt .-%, B5 vitamins in amounts of 0.5 to 10 wt , -%, in particular 1 to 5 wt .-%, preferably 1.2 to 4 wt .-%, B6 vitamins in amounts of 0.1 to 5 wt .-%, in particular 0.5 to 3 wt .-% , preferably 0.8 to 1.3 wt .-%, B9 vitamins in amounts of 0.01 to 1 wt .-%, in particular 0.05 to 0.5 wt .-%, preferably 0.1 to 0, 3 wt .-%, Bia vitamins in amounts of 0.0003 to 0.01 wt .-%, in particular 0.0009 to 0.008 Ge % by weight, preferably 0.001 to 0.01% by weight, of D vitamins in amounts of 0.0002 to 0.01% by weight, in particular 0.0008 to 0.008% by weight, preferably 0.001 to 0.01 Wt .-%, a Ubiquinon-10 component in amounts of 2 to 25 wt .-%, in particular 5 to 15 wt%, preferably 6 to 12 wt .-%, and B7-Vrtamine in amounts of 0.001 to 0.5 % By weight, in particular 0.007 to 0.1 wt .-%, preferably 0.01 to 0.08, niacin in amounts of 1 to 20 wt .-%, in particular 3 to 15 wt .-%, preferably 5 to 11 wt .-%, zinc and / or a zinc compound in amounts of 0.2 to 5 wt .-%, in particular 1 to 4.5 wt .-%, preferably 1.5 to 3.5 wt .-%, magnesium and / or a magnesium compound in amounts of from 10 to 50% by weight, in particular from 15 to 40% by weight, preferably from 25 to 35% by weight, of selenium and / or a selenium compound in amounts of from 0.001 to 0.1% by weight , in particular 0.007 to 0.08 wt .-%, preferably 0.01 to 0.05 wt .-%, and iron and / or an iron compound in amounts of 0.5 to 10 wt .-%, in particular 1 to 5 Wt .-%, preferably 1.5 to 3 wt .-%, based on the total weight of the therapeutically active agents of the combination preparation are included. Gonadosan GmbH by AnwäiteBuraer & Partner Rechtsanwalt GmbH POSSIBLE A2011 / 01312 ιοιη // ιηιι 11 · 'in Nr R7RR P.019 / 020
    类似技术:
    公开号 | 公开日 | 专利标题
    EP1978949B1|2012-10-17|Combination preparation for improving sperm quality
    DE69814834T2|2004-04-08|NUTRITIONAL COMPOSITION TO IMPROVE CELL ENERGY
    EP1474142B1|2010-04-28|Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof
    DE19528461A1|1997-02-06|Preparation for nutrition
    DE60104853T2|2005-08-18|Compositions comprising folic acid and zinc to improve sperm quality
    EP2648807B1|2018-01-24|Combination preparation for improving female fertility
    DE202013002760U1|2014-06-23|Dietary supplement for medication-oriented supplementation
    WO2019166418A1|2019-09-06|Nutraceutical or pharmaceutical composition
    EP2929879B1|2020-03-18|Combination preparation for treating infertility which is associated to endometriosis
    EP1853267B9|2013-05-15|Folic acid-, vitamin b6- and vitamin b12-containing agents and the use thereof
    DE102007053369A1|2009-07-02|Use of a preparation containing a creatine-component and a further component of e.g. L-carnitine, acetyl-L-carnitine, arginine, glutathione, vitamin C and vitamin E, as a dietary supplement for improving the male fertility in vertebrates
    WO2016108195A1|2016-07-07|Hair restorer preparation or food supplement
    EP2736354B1|2017-08-16|Use of citrulline and combination compound for improving male fertility
    EP1437051B1|2010-12-29|Ocuvite Lutein
    US9662361B1|2017-05-30|Method for treating azoospermia
    AT510761A1|2012-06-15|USE OF A UBIQUINONE COMPONENT AND A COMBINATION PREPARATION TO IMPROVE FEMALE FERTILITY
    EP3090638B1|2020-05-06|Nutritional supplement to treat signs of vitamin d3 deficiency
    WO2008003484A2|2008-01-10|Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories
    WO2005074950A1|2005-08-18|Utilization of mare's milk for the production of a preparation to improve sperm quality
    EP1675598B1|2009-09-16|Nutrition trace element composition
    DE19830768A1|2000-01-13|Creatine-containing comprises neurotransmitter and alpha-liponic acid useful for treating muscular dystrophy and for preventing obesity in muscular dystrophy sufferers
    AT518311A1|2017-09-15|combination preparation
    AT9808U1|2008-04-15|VITAMIN AND MINERAL MATERIAL PREPARATION AND ITS USE FOR IMPROVING THE SEED QUALITY
    EP1437052A1|2004-07-14|Ocuvite Zinc
    JP2009256364A|2009-11-05|Method and composition for improving health state of fertilizing capacity of male and female animal and human
    同族专利:
    公开号 | 公开日
    WO2012076680A1|2012-06-14|
    AT510810B1|2017-09-15|
    EP2648807B1|2018-01-24|
    EP2648807A1|2013-10-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US6579544B1|2000-05-31|2003-06-17|Nutriex, L.L.C.|Method for supplementing the diet|
    WO2002076436A2|2001-03-27|2002-10-03|Jaap Meijer|Modular system of dietary supplement compositions comprising vitamins|
    US20080187526A1|2002-08-28|2008-08-07|Prasad Kedar N|Micronutrient formulations for hearing health|
    US20040082536A1|2002-10-25|2004-04-29|Cooper Kenneth H.|Multi-vitamin and mineral supplement|
    AU2008100822A4|2007-08-28|2008-10-16|Blackmores Limited|Nutrition supplement|
    US6569857B1|1999-05-03|2003-05-27|Drugtech Corporation|Dietary supplement|
    DE60027415T2|2000-06-16|2006-10-19|Rath, Matthias, Dr.med.|A smooth muscle disease prevention composition containing ascorbate, arginine and magnesium|
    EP1195159B1|2000-10-09|2006-05-31|Rath, Matthias, Dr. med.|Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer|
    US20050208651A1|2002-03-08|2005-09-22|Ri-Cheng Chian|Vitro maturation of immature human oocytes|
    AT503484A1|2004-02-10|2007-10-15|Oekopharm Forschungs Und Entwi|USE OF MARINE MILK FOR THE MANUFACTURE OF A PREPARATION FOR THE TREATMENT OF BARRENESS|
    US20070104801A1|2005-11-07|2007-05-10|Ivf Online Llc|Fertility and anti-aging supplement for the fertility health of females and males|CN105792818B|2013-12-05|2019-07-12|希格马托制药工业公司|For promoting the composition of female fertility|
    WO2015089656A1|2013-12-20|2015-06-25|Fertilify Inc.|Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health|
    EP2929879B1|2014-04-07|2020-03-18|Gonadosan GmbH|Combination preparation for treating infertility which is associated to endometriosis|
    WO2020128876A1|2018-12-19|2020-06-25|Presinus Pharmaceuticals Private Limited|Composition comprising iodine; selenium, vitamin d3 and lycopene for the prevention and treatment of hypothyroidism|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    AT20372010A|AT510761A1|2010-12-09|2010-12-09|USE OF A UBIQUINONE COMPONENT AND A COMBINATION PREPARATION TO IMPROVE FEMALE FERTILITY|
    ATA1312/2011A|AT510810B1|2010-12-09|2011-09-13|COMBINATION PROCEDURE FOR IMPROVING FEMALE FERTILITY|ATA1312/2011A| AT510810B1|2010-12-09|2011-09-13|COMBINATION PROCEDURE FOR IMPROVING FEMALE FERTILITY|
    PCT/EP2011/072298| WO2012076680A1|2010-12-09|2011-12-09|Combination preparation for improving female fertility|
    EP11796676.2A| EP2648807B1|2010-12-09|2011-12-09|Combination preparation for improving female fertility|
    [返回顶部]